Overview

A Gastrointestinal Quality of Life Study in Lung Transplant Recipients Converted From Mycophenolate Mofetil to Myfortic

Status:
Unknown status

Trial end date:
0000-00-00

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate gastrointestinal (GI) symptoms and health related quality of life in lung transplant recipients converted from Mycophenolate Mofetil (MMF) to Myfortic as part of standard immunosuppressive therapy.

Phase:

Phase 4

Details

Lead Sponsor:

Vanderbilt University

Collaborator:

Novartis Pharmaceuticals

Treatments:

Mycophenolate mofetil
Mycophenolic Acid